H. Krum

Comparison of a supra-sternal cardiac output monitor (USCOM) with the pulmonary artery catheter (2009)

Thom, O., Taylor, D. M., Wolfe, R. E., Cade, J., Myles, P., Krum, H., ...

Background Cardiac output (CO) cannot reliably be estimated by clinical examination. We aimed to measure the agreement between CO measurements using a supra-sternal Doppler monitor (USCOM, Coffs...

Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse events in the elderly in Australia. ASPirin in Reducing Events in the Elderly (ASPREE) (2008)

Nelson, MR, Reid, CM, Ames, D, Beilin, LJ, Donnan, GA, Gibbs, P, ...

Aim: To determine the feasibility of performing a large clinical trial of the use of aspirin for the primary prevention of cardiovascular disease in older participants — the ASPirin in Reducing...

Circuit resistance training in chronic heart failure improves skeletal muscle mitochondrial ATP production rate - A randomised controlled trial (2007)

Williams, AD, Carey, MF, Selig, S, Krum, H, Hayes, A, Patterson, J, ...

Background: We aimed to determine the role of skeletal muscle mitochondrial ATP production rate (MAPR) in relation to exercise tolerance after resistance training (RT) in chronic heart failure (CHF)....

Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat (2007)

Connelly, K.A., Kelly, D.J., Zhang, Y., Prior, D.L., Martin, J., Cox, A.J., ...

Objective Diabetic cardiomyopathy is an increasingly recognized cause of cardiac failure despite preserved left ventricular systolic function. Given the over-expression of angiotensin II in human...

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence - Results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III (2005)

Van Veldhuisen, DJ, Silke, B, Erdmann, E, Follath, F, Krum, H, ...

Background - In patients with chronic heart failure (CHF), a beta-blocker is generally added to a regimen containing an angiotensin-converting-enzyme ( ACE) inhibitor. It is unknown whether...